Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
SHILPAMED
Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm · Raichur, India
₹611.25
▲+1.38%SHILPAMED is trading in the upper third of its 1-year range, likely driven by its impressive 31.50% revenue growth and the overall growth prospects in the healthcare sector
Exchange
NSI
Currency
INR
Day range
₹601.15 – ₹614.95
52-week range
₹259.50 – ₹650.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis70% confidence
The current price of 611.25 INR seems reasonable considering the company's growth prospects and the industry's outlook, but a more in-depth analysis of the financials and industry trends is necessary to determine the exact fair value
6.0% below the 1-year high · trend up
Hedge-fund memo
Today
The stock has seen a slight increase of 1.38% today, indicating a positive sentiment among investors
This week
The weekly trend is not provided, but the stock's movement in the upper third of its 1-year range suggests a bullish outlook
This month
The monthly trend is also not provided, but the overall growth in the healthcare sector could contribute to a positive trend
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
3 headlines · 1 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 3 recent quarters (EPS actual vs. consensus).
4.3655 vs 3.3
32.29% surprise
2.8588 vs 2.8
2.10% surprise
2.25 vs 4.4
-48.86% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| SHILPAMED | 119.55B | 49.21 | 9.82% | 20.39% | 31.50% |
| INDOCO | 19.97B | 637.32 | — | 1.39% | 6.80% |
| CAPLIPOINT | 192.79B | 30.14 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory changes in the pharmaceutical industry
Mitigation: Diversification and ongoing monitoring of regulatory developments
Business intelligence
Competitive moat
SHILPAMED's competitive moat lies in its established position in the Indian pharmaceutical market and its ability to capitalize on the growing demand for specialty and generic drugs
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Release of quarterly or annual financials
Thesis builder
Bull case
The company's strong revenue growth and growing demand for its products could drive the stock price up
Base case
The current valuation seems reasonable, but investors should be cautious of the high P/E ratio
Bear case
The debt/equity ratio and regulatory risks could negatively impact the stock price
Time horizon
Medium to long-term
Est. CAGR
15-20%
Entry (qual.)
On dips or when the stock pulls back to the lower end of its range
Exit (qual.)
If the stock reaches the upper end of its 1-year range or when the company's growth prospects diminish
Overall conviction 70%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how SHILPAMED fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain SHILPAMED for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Investors may consider accumulating SHILPAMED stock given its growth prospects and the overall industry outlook
MarketWatch·2d ago·stock up, lagging market
MarketWatch·3d ago·stock rallies, beats peers
MarketWatch·4d ago·stock rallies, outperforms market
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 19.94% |
| 30.90% |
| 19.00% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% | 16.48% | -4.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹601.15
Resistance (day/52w high)
₹614.95
Volume
4,86,209
Trend
up
RSI (14)
42
MACD
bearish
MA cross
golden
50-day MA
₹572.45
200-day MA
₹407.14
vs 200-DMA
50.1%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.